Multiple Myeloma Clinical Trial

Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma

Summary

The purpose of this study is to understand if small proteins found on the surface of myeloma cells (called CXCR4 and CD47) or inside the myeloma cells (Pim kinases, sphingolipids, and pS6) can predict how patients will respond to chemotherapy-treatment and if a small molecule inside the myeloma cells (called Pim kinase) can be used as a treatment target for myeloma. A sample from the bone marrow biopsy (a small amount of tissue removed from the body for laboratory testing) and aspirate (a small amount of fluid is removed from the body for laboratory testing) that had been done before the subject entered this study will be provided for research purposes. Based on preliminary data, it is hypothesized that CXCR4, CD47, sphingolipids, and Pim kinases could be used as prognostic/predictive markers and that Pim kinase inhibitors provide a new agent for the treatment of multiple myeloma.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

A diagnosis of multiple myeloma or possible multiple myeloma who will have a bone marrow biopsy and aspirate
Planned therapy with standard chemotreatment for multiple myeloma
Laboratory data such as calcium, beta 2-microglobulin, albumin, creatinine and bone survey available for staging purpose.
≥18 years old

Exclusion Criteria:

< 18 years old
Patients who will not receive chemotreatment
Patients whose treatment records are not available

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

73

Study ID:

NCT01410981

Recruitment Status:

Completed

Sponsor:

Medical University of South Carolina

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Medical University of South Carolina
Charleston South Carolina, 29425, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

73

Study ID:

NCT01410981

Recruitment Status:

Completed

Sponsor:


Medical University of South Carolina

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider